Table 1.
Baseline characteristics
| Abacavir | Nevirapine | |
|---|---|---|
| Total participants | 300 (100%) | 300 (100%) |
| Randomization in main DART trial | ||
| Laboratory and clinical monitoring | 150 (50%) | 149 (50%) |
| Clinical monitoring only | 150 (50%) | 151 (50%) |
| Centre | ||
| Entebbe, Uganda | 149 (50%) | 151 (50%) |
| JCRC, Uganda | 151 (50%) | 149 (50%) |
| Sex | ||
| Male | 83 (28%) | 87 (29%) |
| Female | 217 (72%) | 213 (71%) |
| Age (years) | ||
| ≤30 | 43 (14%) | 68 (23%) |
| >30–35 | 69 (23%) | 55 (18%) |
| >35–40 | 75 (25%) | 90 (30%) |
| >40–45 | 64 (21%) | 41 (14%) |
| >45–50 | 31 (10%) | 32 (11%) |
| >50 | 18 (6%) | 14 (5%) |
| Median (IQR) | 37.6 (31.9–42.3) | 36.3 (30.7–41.4) |
| WHO disease stage | ||
| 2 | 83 (28%) | 76 (25%) |
| 3 | 173 (58%) | 157 (52%) |
| 4 | 44 (15%) | 67 (22%) |
| CD4 (cells/mm3) | ||
| 0–49 | 76 (25%) | 88 (29%) |
| 50–99 | 75 (25%) | 62 (21%) |
| 100–149 | 75 (25%) | 84 (28%) |
| 150–199 | 74 (25%) | 66 (22%) |
| Median (IQR) [range] | 99 (49–149) [1–199] | 100 (40–145) [1–199] |
| Body mass index (BMI): median (IQR) | 20.9 (18.9–23.5) | 21.3 (19.3–23.8) |
| Haemoglobin (g/dl): mean (SD) | 11.5 (1.8) | 11.6 (1.7) |
| Neutrophils (×109/l): mean (SD) | 1.5 (0.7) | 1.6 (0.9) |
| Glomerular filtration rate (ml/min/1.73 m2)*: mean (SD) | 85 (27) | 85 (20) |
| ALT (IU): mean (SD) | 27 (19) | 27 (16) |
| AST (IU): mean (SD) | 37 (25) | 37 (20) |
| Women prescribed ARVs to prevent MTCT before entering DART (% of women) | 4 (2%) | 11 (5%) |
| Cotrimoxazole prophylaxis† | 120 (40%) | 125 (42%) |
The median CD4 at baseline is 99 rather than 99.5 cells/mm3 (as designed), because one participant was randomized in the wrong CD4 stratum in error.
ARV, antiretroviral; WHO, world health organisation.
*
Calculated according to the Cockcroft–Gault formula and adjusted for body surface area.
†
Including prophylaxis prescribed on the day of randomization.